MARLBOROUGH, Mass.,
Aug. 28, 2018 /PRNewswire/
-- RXi Pharmaceuticals Corporation (NASDAQ: RXII) a
biotechnology company developing the next generation of
immuno-oncology therapeutics based on its proprietary
self-delivering RNAi (sd-rxRNA®) therapeutic platform today
announced that it will be featured as a presenting company at the
20th Annual Rodman & Renshaw Global Investment
Conference, sponsored by H.C. Wainwright & Co., LLC. The
conference is being held September 4-6,
2018 at the St. Regis New York Hotel in New York City.
Logo -
http://mma.prnewswire.com/media/594748/RXi_Pharmaceuticals_Corporation_Logo.jpg
Dr. Gerrit Dispersyn, Chief Development Officer for the Company,
will provide an overview of RXi's business and ongoing programs for
the development of RNAi-based immuno-oncology therapeutics that aim
to fill the unmet need of other therapeutic approaches and, its
strategy to tackle different immune escape mechanisms to treat
cancer.
Date: Wednesday, September
5, 2018
Time: 3:25 p.m. Eastern
Time
Location: Library, 2nd floor at the St.
Regis New York Hotel in New York
City
Webcast link:
http://wsw.com/webcast/rrshq28/rxii/
About this Conference
If you are an institutional investor and would like to attend
RXi's presentation, please click on the following link
(www.rodmanevents.com) to register for the conference. Once
your registration is confirmed, you will be prompted to log into
the conference website to request a one-on-one meeting with
RXi.
About Immunotherapy of Cancer
Immunotherapy of cancer has become increasingly important in
clinical practice over the recent decade. By activating the
patient's immune system, immunotherapy treatments have shown
remarkable promise in extending the lifespan of previously
untreatable cancer patients. Adoptive cell therapy is an
emerging immunotherapy approach which uses immune cells, such as
T-lymphocytes or NK cells that are isolated from the patient or
retrieved from allogeneic immune cell banks, and then expanded and
in some cases processed to express tumor-binding
receptors.
A new and important step in
this ex-vivo processing of the immune cells is in
development where self-delivering RNAi compounds (sd-rxRNA®) are
used to eliminate the expression of immunosuppressive receptors or
proteins from the therapeutic immune cells, thereby making them
less sensitive to tumor resistance mechanisms and improving their
ability to destroy tumor cells. In this way, sd-rxRNA
therapeutic compounds can be used to weaponize therapeutic immune
cells to attack cancer and ultimately provide patients battling
terminal cancers with a powerful new treatment option that goes
beyond current treatment modalities.
About RXi Pharmaceuticals
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
biotechnology company developing the next generation of
immuno-oncology therapeutics based on its self-delivering RNAi
(sd-rxRNA®) therapeutic platform. The Company's discovery and
research efforts are focused on developing sd-rxRNA therapeutic
compounds to be used with an Adoptive Cell Transfer (ACT) approach.
This process uses immune cells, such as T-lymphocytes that are
isolated from the patient or retrieved from allogeneic immune cell
banks, and then expanded and in some cases processed to express
tumor-binding receptors. Our approach introduces a new and
important step in ex-vivo processing of the immune cells where
sd-rxRNA is used to eliminate the expression of immunosuppressive
receptors or proteins from the therapeutic immune cells, making
them less sensitive to tumor resistance mechanisms and thus
improving their ability to destroy the tumor cells. Essentially, we
aim to maximize the power of our sd-rxRNA therapeutic compounds by
weaponizing therapeutic immune effector cells to attack cancer and
ultimately provide patients battling terminal cancers with a
powerful new treatment option that goes beyond current treatment
modalities.
For additional information, visit the Company's website,
www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are neither historical facts nor
assurances of future performance. These statements are based only
on our current beliefs, expectations, and assumptions regarding the
future of our business, future plans and strategies, projections,
anticipated events and trends, the economy and other future
conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict and many of
which are outside of our control. Our actual results may differ
materially from those indicated in the forward-looking statements
as a result of a number of important factors, including the safety
and efficacy of our product candidates, future success of our
clinical trials and scientific studies, our ability to enter into
strategic partnerships and the future success of these strategic
partnerships, the availability of funds and resources to pursue our
research and development projects and general economic conditions.
Our Annual Report on Form 10-K and subsequent Quarterly Reports on
Form 10-Q include detailed risks under the caption "Risk Factors"
that may affect our business, results of operations and financial
condition. Readers are urged to review these risk factors and to
not act in reliance on any forward-looking statements, as actual
results may differ from those contemplated by our forward-looking
statements. RXi does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release.
Contact RXi Pharmaceuticals Corporation
Tamara McGrillen
Tel: +1 508-929-3646
Email: tmcgrillen@rxipharma.com
View original
content:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-to-present-at-the-20th-annual-rodman--renshaw-global-investment-conference-300703234.html
SOURCE RXi Pharmaceuticals Corporation